Vaxart Inc (VXRT)
0.7289
-0.02
(-2.68%)
USD |
NASDAQ |
May 03, 16:00
0.7419
+0.01
(+1.78%)
After-Hours: 20:00
Vaxart Enterprise Value: 87.01M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 87.01M |
| May 02, 2024 | 90.51M |
| May 01, 2024 | 82.09M |
| April 30, 2024 | 84.55M |
| April 29, 2024 | 84.30M |
| April 26, 2024 | 83.68M |
| April 25, 2024 | 74.76M |
| April 24, 2024 | 83.68M |
| April 23, 2024 | 89.88M |
| April 22, 2024 | 92.86M |
| April 19, 2024 | 91.66M |
| April 18, 2024 | 106.73M |
| April 17, 2024 | 110.87M |
| April 16, 2024 | 115.79M |
| April 15, 2024 | 118.34M |
| April 12, 2024 | 118.52M |
| April 11, 2024 | 141.10M |
| April 10, 2024 | 135.89M |
| April 09, 2024 | 141.10M |
| April 08, 2024 | 148.06M |
| April 05, 2024 | 148.06M |
| April 04, 2024 | 156.75M |
| April 03, 2024 | 174.14M |
| April 02, 2024 | 175.88M |
| April 01, 2024 | 186.31M |
| Date | Value |
|---|---|
| March 28, 2024 | 186.31M |
| March 27, 2024 | 184.57M |
| March 26, 2024 | 172.40M |
| March 25, 2024 | 174.14M |
| March 22, 2024 | 179.35M |
| March 21, 2024 | 174.14M |
| March 20, 2024 | 175.88M |
| March 19, 2024 | 161.97M |
| March 18, 2024 | 161.97M |
| March 15, 2024 | 148.06M |
| March 14, 2024 | 151.53M |
| March 13, 2024 | 156.75M |
| March 12, 2024 | 158.49M |
| March 11, 2024 | 160.23M |
| March 08, 2024 | 167.18M |
| March 07, 2024 | 153.27M |
| March 06, 2024 | 162.84M |
| March 05, 2024 | 164.53M |
| March 04, 2024 | 167.06M |
| March 01, 2024 | 171.28M |
| February 29, 2024 | 166.22M |
| February 28, 2024 | 178.87M |
| February 27, 2024 | 174.65M |
| February 26, 2024 | 167.90M |
| February 23, 2024 | 174.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-16.37M
Minimum
Dec 27 2022
2.446B
Maximum
Feb 02 2021
308.51M
Average
161.15M
Median
Oct 03 2022
Enterprise Value Benchmarks
| Novavax Inc | 289.48M |
| aTyr Pharma Inc | 10.72M |
| Allogene Therapeutics Inc | 70.42M |
| AIM ImmunoTech Inc | 7.819M |
| Protalix BioTherapeutics Inc | 58.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.38M |
| Revenue (Quarterly) | 6.625M |
| Total Expenses (Quarterly) | 23.52M |
| EPS Diluted (Quarterly) | -0.12 |
| Profit Margin (Quarterly) | -262.3% |
| Earnings Yield | -79.57% |
| Normalized Earnings Yield | -79.57 |